Comparison of Whole Body DWI to FDG PET

StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 7 more changesShow less
    • Final enrollment: 25 participants (planned 30)
    • Primary completion moved earlier from Oct 31, 2027 to Apr 30, 2027
    • Study completion moved earlier from Oct 31, 2029 to Apr 30, 2029
    • Interventions: Fluorodeoxyglucose F18 (Drug), General Electric (GE) SIGNA PET/MR (Device), Positron Emission Tomography combined with Magnetic resonance… to Fluorodeoxyglucose F18 (Drug), General Electric (GE) SIGNA PET/MR (Device), Positron Emission Tomography combined with Magnetic resonance…
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
  2. Re-verified, no change to tracked fieldsv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 28, 2025 to Feb 6, 2025
    • Eligibility criteria expanded, about 20 words
    • Site details revised
    v3
  4. Start date: Nov 30, 2024 to Feb 28, 2025
    • Primary completion date: Jul 31, 2027 to Oct 31, 2027
    • Study completion date: Jul 31, 2029 to Oct 31, 2029
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.
Trial Details
NCT Number NCT06630845
Lead Sponsor University of California, San Francisco
Collaborators: Society of Abdominal Radiology, GE Healthcare
Conditions
(from sponsor)		 Metastatic Cancer
Related terms Neoplasm Metastasis
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov